Game-changing solutions for an unmet need

Mercurio’s mission is to treat disease and develop novel healthcare solutions through the rapid deployment of promising pharmaceutical, biotechnology and devices in advanced states of development.
Learn More

Seconds Count

Every 20 seconds, someone in the world loses a limb to diabetes.

25% of diabetic patients will be affected by Diabetic Foot Ulcer in their lifetime. 6% of Diabetics have a DFU, 50% of DFU’s develop infection, and 35% do not heal properly.

Diabetes & DFU

Diabetes Mellitus (DM): Affects 9.3%, or 45 million of 485 million of North Americans, increasing in incidence to 12%+ and 65 million by 2030*.

DM patients have a 25% Lifetime DFU Risk.



U.S. Annual Medical Costs ($USD – Billions)

Diabetic Foot Complications

Breast Cancer

Colorectal Cancer

Lung Cancer

Cuba and America Together

Mercurio Biotec, LLC

has entered into exclusive licensing agreements with the Center for Genetic Engineering and Biotechnology (CIGB), to conduct all transactions necessary to import Heberprot-P and conduct independent clinical trials authorized by the U.S. Food and Drug Administration (FDA) and commercialize in the United States.

Collaborative Culture

On June 13, 2016, the United States Department of Health and Human Services and the Ministry of Public Health of the Republic of Cuba have signed a Memorandum of Understanding to foster a collaborative culture of research, innovation, and cooperation in the fields of healthcare delivery, biomedical and clinical sciences.

Meeting Global Needs

Furthermore, the aforementioned MOU addresses the development of Cooperative Health Strategies that includes Diabetes, Clinical Trials and Medical Product Regulation.

Connect with Mercurio

Get in touch with Mercurio Biotec to learn more about our mission!